CytoMed Therapeutics Ltd
F98
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,175.10 | 49.90 | 0.61% |
CAC 40 | 7,536.26 | 33.48 | 0.45% |
DAX 40 | 22,242.45 | 177.94 | 0.81% |
Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
FTSE 100 | 8,415.25 | 7.81 | 0.09% |
HKSE | 21,980.74 | 70.98 | 0.32% |
NASDAQ | 17,382.94 | 216.90 | 1.26% |
Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
S&P 500 | 5,525.21 | 40.44 | 0.74% |
S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
SSE Composite Index | 3,295.06 | 2.23 | -0.07% |